A phase I randomized, double-blind trial of the safety and immunogenicity of FluMist, a live, intranasal influenza virus vaccine versus placebo in immunocompromised children ages 5 through 17 years of age
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 04 May 2009 Status changed from recruiting to completed.
- 04 May 2009 Status cahnge from recruiting to completed
- 02 May 2009 Results presented at 2009 Annual Meeting of the Pediatric Academic Societies